These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 17289876)

  • 1. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
    Libè R; Groussin L; Tissier F; Elie C; René-Corail F; Fratticci A; Jullian E; Beck-Peccoz P; Bertagna X; Gicquel C; Bertherat J
    Clin Cancer Res; 2007 Feb; 13(3):844-50. PubMed ID: 17289876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
    Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
    Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors.
    Gicquel C; Bertagna X; Gaston V; Coste J; Louvel A; Baudin E; Bertherat J; Chapuis Y; Duclos JM; Schlumberger M; Plouin PF; Luton JP; Le Bouc Y
    Cancer Res; 2001 Sep; 61(18):6762-7. PubMed ID: 11559548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
    Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
    Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Loss of heterozygosity fine mapping of chromosome 17p13 in transitional cell carcinoma of human urinary bladder].
    Zheng S; Zhang J; Di X; Xiao Z; Wang D; Li C; He Z; Han N; Guo S; Cheng S; Gao Y
    Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):161-3. PubMed ID: 11953150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas.
    Plisiecka-Hałasa J; Dansonka-Mieszkowska A; Kraszewska E; Dańska-Bidzińska A; Kupryjańczyk J
    Anticancer Res; 2008; 28(2A):989-96. PubMed ID: 18507046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
    Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
    Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity.
    Bertherat J; Groussin L; Sandrini F; Matyakhina L; Bei T; Stergiopoulos S; Papageorgiou T; Bourdeau I; Kirschner LS; Vincent-Dejean C; Perlemoine K; Gicquel C; Bertagna X; Stratakis CA
    Cancer Res; 2003 Sep; 63(17):5308-19. PubMed ID: 14500362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
    Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
    Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors.
    Soon PS; Libe R; Benn DE; Gill A; Shaw J; Sywak MS; Groussin L; Bertagna X; Gicquel C; Bertherat J; McDonald KL; Sidhu SB; Robinson BG
    Ann Surg; 2008 Jan; 247(1):157-64. PubMed ID: 18156936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer.
    Roncuzzi L; Brognara I; Baiocchi D; Amadori D; Gasperi-Campani A
    Oncol Rep; 2005 Aug; 14(2):471-4. PubMed ID: 16012732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between loss of heterozygosity at microsatellite loci and computerized nuclear morphometry in hepatocellular carcinoma.
    Suzuki K; Hirooka Y; Tsujitani S; Yamane Y; Ikeguchi M; Kaibara N
    Anticancer Res; 2000; 20(2B):1257-62. PubMed ID: 10810431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
    Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
    Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of the TP53 gene in human gliomas.
    Rasheed BK; McLendon RE; Herndon JE; Friedman HS; Friedman AH; Bigner DD; Bigner SH
    Cancer Res; 1994 Mar; 54(5):1324-30. PubMed ID: 8118823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters.
    Seitz S; Poppe K; Fischer J; Nothnagel A; Estévez-Schwarz L; Haensch W; Schlag PM; Scherneck S
    J Pathol; 2001 Jul; 194(3):318-26. PubMed ID: 11439364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p.
    Beghelli S; Pelosi G; Zamboni G; Falconi M; Iacono C; Bordi C; Scarpa A
    J Pathol; 1998 Sep; 186(1):41-50. PubMed ID: 9875139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
    Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
    Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.
    Ott K; Vogelsang H; Mueller J; Becker K; Müller M; Fink U; Siewert JR; Höfler H; Keller G
    Clin Cancer Res; 2003 Jun; 9(6):2307-15. PubMed ID: 12796400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma.
    Obermann EC; Diss TC; Hamoudi RA; Munson P; Wilkins BS; Camozzi ML; Isaacson PG; Du MQ; Dogan A
    J Pathol; 2004 Feb; 202(2):252-62. PubMed ID: 14743509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.